Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 504 across all filing types
Latest filing 2026-04-21 Proxy Solicitation & In…
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
Proxy Solicitation & Information Statement
2026-04-21 English
ARS - Trevi Therapeutics, Inc. (0001563880) (Filer)
Annual Report
2026-04-21 English
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common stock, including details about the offering size, price, underwriters, and expected proceeds. It also includes a business update and financial condition information but does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). The document is lengthy (15,000 characters) and contains substantive information about a capital raising event. Therefore, it fits the category of a Capital/Financing Update (CAP).
2026-04-17 English
424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a $150 million common stock offering by Trevi Therapeutics, Inc. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and other disclosures typical of a securities offering prospectus. The document references SEC registration numbers and includes disclaimers about the offering not being complete or final. This type of document is a capital raising disclosure, specifically a prospectus supplement for a public offering of common stock. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing unrelated to capital raising. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2026-04-16 English
4 - TREVI THERAPEUTICS, INC. (0001563880) (Filer)
Director's Dealing
2026-02-20 English
4 - TREVI THERAPEUTICS, INC. (0001563880) (Filer)
Director's Dealing
2026-02-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.